Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ferhan Qureshi

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularisYulia Vugmeyster, Joseph Beyer, Kathy Howell, et al.
Arthritis Research & Therapy|September 5, 2015
Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexateAase Haj Hensvold, Vijay Joshua, Wanying Li, et al.
Proteomics. Clinical Applications|February 27, 2023
Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosisFerhan Qureshi, Wayne Hu, Louisa Loh, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 20, 2024
A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosisKian Jalaleddini, Robert A Bermel, Bari Talente, et al.
Multiple Sclerosis and Related Disorders|May 22, 2024
Lower arterial cerebral blood flow is associated with worse neuroinflammation and immunomodulation composite proteomic scoresDejan Jakimovski, Ferhan Qureshi, Murali Ramanathan, et al.
Annals of Clinical and Translational Neurology|January 18, 2024
Proteomic signatures of physical, cognitive, and imaging outcomes in multiple sclerosisKian Jalaleddini, Dejan Jakimovski, Anisha Keshavan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 6, 2026
Longitudinal short-term assessments of single- and multi-protein disease activity biomarkers to determine reliability and the minimum detectable change in people with clinically stable RRMSShannon McCurdy, Elisa Sheng, Kian Jalaleddini, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|April 28, 2025
Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessments in multiple sclerosisAngela Sanchez, Elisa Sheng, Sarah Eagleman, et al.
Medrxiv : the Preprint Server for Health Sciences|July 18, 2023
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect disease activity in multiple sclerosisTanuja Chitnis, Ferhan Qureshi, Victor M Gehman, et al.
Nature Communications|May 20, 2024
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosisTanuja Chitnis, Ferhan Qureshi, Victor M Gehman, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularisYulia Vugmeyster, Joseph Beyer, Kathy Howell, et al.
Arthritis Research & Therapy|September 5, 2015
Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexateAase Haj Hensvold, Vijay Joshua, Wanying Li, et al.
Proteomics. Clinical Applications|February 27, 2023
Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosisFerhan Qureshi, Wayne Hu, Louisa Loh, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 20, 2024
A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosisKian Jalaleddini, Robert A Bermel, Bari Talente, et al.
Multiple Sclerosis and Related Disorders|May 22, 2024
Lower arterial cerebral blood flow is associated with worse neuroinflammation and immunomodulation composite proteomic scoresDejan Jakimovski, Ferhan Qureshi, Murali Ramanathan, et al.
Annals of Clinical and Translational Neurology|January 18, 2024
Proteomic signatures of physical, cognitive, and imaging outcomes in multiple sclerosisKian Jalaleddini, Dejan Jakimovski, Anisha Keshavan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 6, 2026
Longitudinal short-term assessments of single- and multi-protein disease activity biomarkers to determine reliability and the minimum detectable change in people with clinically stable RRMSShannon McCurdy, Elisa Sheng, Kian Jalaleddini, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|April 28, 2025
Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessments in multiple sclerosisAngela Sanchez, Elisa Sheng, Sarah Eagleman, et al.
Medrxiv : the Preprint Server for Health Sciences|July 18, 2023
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect disease activity in multiple sclerosisTanuja Chitnis, Ferhan Qureshi, Victor M Gehman, et al.
Nature Communications|May 20, 2024
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosisTanuja Chitnis, Ferhan Qureshi, Victor M Gehman, et al.
Pageof 3